Efficacy of intermittent dosage regimen of rosuvastatin combined with ezetimibe in treatment of coronary atherosclerotic heart disease
Duan Xiaochun
Han Jing
Jin Liying
Li Nan
Li Zhizhong
Abstract：Objective To explore the effect of intermittent dosage regimen of rosuvastatin combined with ezetimibe on coronary atherosclerotic heart disease(CHD).Methods A total of 85 CHD patients who had statins intolerance from January 2016 to September 2016 in Beijing Anzhen Hospital,Capital Medical University were randomly divided into ezetimibe group(10 mg/d,n =43) and combined treatment group(ezetimibe 10 mg/d and rosuvastatin twice a week,n =42).Blood lipid indexes [total cholesterol(TC),triacylglycerol (TG),high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C)] before treatment and after 12 weeks of treatment were tested and adverse drug effects were recorded.Results Baseline data and reasons for statins intolerance had no significant differences between groups (P ＞ 0.05).TC and LDL-C significantly decreased after treatment compared to the baseline in both groups [ezetimibe group:(4.3 ± 0.8) mmol/L vs (5.2±0.9)mmol/L,(3.2 ±0.6)mmol/L vs (3.9 ±0.8)mmol/L;combined treatment group:(3.8 ±0.6)mmol/Lvs (5.2±0.8)mmol/L,(2.8±0.5)mmol/L vs (3.9 ±0.8)mmol/L](P＜0.05);TG and HDL-C had no significant difference before and after treatment in ezetimibe group;TG in combined treatment group significantly decreased after treatment and HDL-C significantly increased compared to the baseline [(1.4 ±0.4) mmol/L vs (2.2 ± 0.6) mmol/L,(1.6 ± 0.4) mmol/L vs (1.2 ± 0.3) mmol/L] (P ＜ 0.05).TC,TG and LDL-C in combined treatment group were significantly lower than those in ezetimibe group after treatment (P ＜ 0.05).The standard-reaching rate of LDL-C in ezetimibe group was 0;the standard-reaching rate of LDL-C in combined treatment group was 23.8％ (10/42);there was a significant difference between groups (P ＜0.05).No severe adverse reaction was observed during treatment.Conclusion Intermittent dosage regimen of rosuvastatin combined with ezetimibe treating CHD with statins intolerance can improve statins compliance and lipid-lowering effect.
Keywords：Coronary artery diseaseStatins intoleranceRosuvastatinEzetimibe
Publication Date：2017-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 669-672 )